

## Conjugates of bile acid platinum complexes with gold nanoparticles

Emilio Rodríguez-Fernández<sup>a</sup>, Ángel Alonso-Mateos<sup>b</sup>, M<sup>a</sup> Jesús Almendral-Parra<sup>b</sup>, Julio J Criado-Talavera<sup>a</sup>, Manuel Fuentes<sup>c</sup>, Juan Luis Manzano-Iscar<sup>a</sup>, Alberto Orfao<sup>c</sup>, Sara Sánchez-Paradinas<sup>b</sup>

<sup>a</sup> Departamento de Química Inorgánica; <sup>b</sup> Departamento de Química Analítica, Facultad de Ciencias Químicas Universidad de Salamanca, 37008-Salamanca, Spain. <sup>c</sup> Centro de Investigación del Cáncer (CIC; IBMCC CSIC/USAL) Servicio de Citometría, Departamento de Medicina and IBSAL, Universidad de Salamanca 37007 Salamanca, Spain.

[erodri@usal.es](mailto:erodri@usal.es)

### Abstract

The bisursodeoxycholate(ethylenediamine)platinum(II), [Pt(UDC)<sub>2</sub>(en)], PtU2 compound was synthesized according to the procedure of Criado et al.[1-3]

The conjugates of PtU2 with gold nanoparticles (PtU2-AuNP) were prepared by mixing the solid PtU2 compound directly in the colloidal solution of the nanoparticles. All the solutions were vortexed for at least twenty minutes and then stored at 4 °C until use in cell cultures. The conjugates were characterized by UV-visible spectroscopy, fluorescence emission spectroscopy, transmission electron microscopy (TEM) and scanning electron microscopy (SEM) (Figures 1 and 2).

The PtU2-AuNP complex exerted an important cytotoxic activity against MG63 osteosarcoma cells which was already clearly detectable after 48 h of culture (Figure 3) [4]. The precise mechanisms by which the presence of AuNPs increases the cytotoxic activity of the drug remain elusive and require further investigations.

### References

[1] M. Pérez-Andrés, J. J. Benito, E. Rodríguez-Fernández, B. Corradetti, D. Primo, J. L. Manzano, Alberto Orfao and Julio J. Criado. Dalton Trans. (2008) 6159-6164.

[2] Criado, J J; Rodríguez, E; Manzano J L; Alonso, A; Barrena, S; Medarde, M; Pelaez, R; Tabernero, M D; Orfao, A. Bioconjugate Chem. **16** (2005) 275-282.

[3] Pérez-Andrés, M.; Benito, J. J.; Rodríguez-Fernández, E.; Manzano, J. L.; Barrena, S.; Orfao, A.; Criado, J. J. Letters in Drug Desing and Discovery, **4** (2007) 341-345.

[4] Pending of publication.


### Acknowledgment

This work has been supported by a grant from the Foundation "Samuel Solórzano Barruso (2013)"



## Figures

**Figure 1.** Fluorescence of PtU2 and its adduct with AuNp.

AuNp20 ( $c = 7 \cdot 10^{11}$  Np/mL) (Au)  
 PtU2 ( $c = 4,5 \cdot 10^{-4}$  M) (Pt)  
 Adduct 1:1 (Au+Pt)




**Figure 2.** (A)  $^1\text{H-NMR}$  spectra of the platinum compound (i) and its incubation adduct with gold nanoparticles (ii). HUDC = ursodeoxycholic acid. TEM (B) and SEM (C) images of the PtU2-AuNPs conjugate drug complex in water. After adducts formation, the corresponding  $^1\text{H-NMR}$  signals (methyl groups C18, C19 and C21), slightly shifted to 0.55 ppm, 0.79 ppm and 0.85 ppm, respectively.



**Figure 3**

Cytotoxic activity of the PtU2 compound (straight line) and the newly-synthesized PtU2-AuNP complex (curved line) against MG63 (osteosarcoma) cells. Cytotoxic activity against MG63 osteosarcoma cells which was already clearly detectable after 48 h of culture. Cytotoxic activity is specific for the PtU2-AuNPs complex, since no cytotoxic activity was detected when the cells were incubated with the AuNPs alone.



**B**